The North America dipeptidyl peptidase 4 (DPP-4) inhibitors market is anticipated to grow significantly at a CAGR of 3.4% over the forecast period (2020-2026). The growth of the North America dipeptidyl peptidase 4 (DPP-4) inhibitors industry in the region is primarily driven by the increase in the number of cases of diabetes type 2 in the North American region. As per the International Diabetes Federation IDF 2019, over 31.0 million people were suffering from diabetes in the US and approximately 16 million people in Canada. The total number of cases in the US is projected to witness an upsurge owing to the changing lifestyles of the people, thus, it is projected by the IDF that in 2030 the total number of cases is expected to surpass 34.4 million and over 36.0 million cases in 2045. Thus, an increased number is likely to create a scope for market growth.
To Request a Sample of our Report on North America Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market: https://www.omrglobal.com/request-sample/north-america-europe-dipeptidyl-peptidase-4-inhibitors-market
However, there are severe side effects associated with the consumption of the drug is likely to challenge the growth of the market. Additionally, in 2015, the US FDA had warned regarding the intake of the DPP-4 inhibitors. It results in severe joint pain. Nevertheless, the drug can be taken with a specific diet and exercise for lowering the blood sugar levels in adults suffering from type 2 diabetes. Furthermore, the contributions by the key players in order to develop advanced and safe drugs may create significant scope for the market growth over the forecast period.
Market Coverage
- Market number available for – 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type
- Regions Covered- North America
- Competitive Landscape- Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Merck & Co., Eli Lily & Co., GlaxoSmithKline Plc, LG Life Sciences Ltd., Novartis AG, Phenomix Corp., and Takeda Pharmaceutical Co. among others
(Get 15% Discount on Buying this Report)
A full Report of North America Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market is Available at: https://www.omrglobal.com/industry-reports/north-america-europe-dipeptidyl-peptidase-4-inhibitors-market
North America Dipeptidyl peptidase 4 (DPP-4) inhibitors Market – Segmentation
By Type
- Sitagliptin
- Vildagliptin
- Saxagliptin
- Linagliptin
- Gemigliptin
- Anagliptin
- Teneligliptin
- Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
